Effects of erythropoietin treatment on cell-mediated immune responses in predialysis patients

References

• Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; ii: 1175–8
   Web of Science ®Google Scholar
• Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial [see comments]. N Engl J Med 1987; 316: 73–8
   PubMed Web of Science ®Google Scholar
• Aljama P, Bommer J, Canaud B, Carrera F, Eckardt KU, Horl WH, et al. Practical guidelines for the use of NESP in treating renal anaemia. Nephrol Dial Transplant 2001; 16(Suppl 3)22–8
   PubMed Web of Science ®Google Scholar
• Hoshino S, Teramura M, Takahashi M, Motoji T, Oshimi K, Ueda M, et al. Expression and characterization of erythropoietin receptors on normal human bone marrow cells. Int J Cell Cloning 1989; 7: 156–67
   PubMedGoogle Scholar
• Pfaffl W, Gross HJ, Neumeier D, Nattermann U, Samtleben W, Gurland HJ. Lymphocyte subsets and delayed cutaneous hypersensitivity in hemodialysis patients receiving recombinant human erythropoietin. Contrib Nephrol 1988; 66: 195–204
   PubMedGoogle Scholar
• Grimm PC, Sinai-Trieman L, Sekiya NM, Robertson LS, Robinson BJ, Fine RN, et al. Effects of recombinant human erythropoietin on HLA sensitization and cell mediated immunity. Kidney Int 1990; 38: 12–8
   PubMed Web of Science ®Google Scholar
• Bárány P, Fehrman I, Godoy C. Long-term effects on lymphocytotoxic antibodies and immune reactivity in hemodialysis patients treated with recombinant human erythropoietin. Clin Nephrol 1992; 37: 90–6
   PubMed Web of Science ®Google Scholar
• Steffensen G, Aunsholt NA, Povlsen JV. Evidence that treatment of ESRD patients with recombinant human erythropoietin induces immunosuppression without affecting the distribution of peripheral blood mononuclear cell subpopulations. Clin Nephrol 1996; 45: 98–103
   PubMed Web of Science ®Google Scholar
• Singh AB, Singh M, Palekar S, Levy S, Nunn C, Mann RA. The effects of recombinant human erythropoietin on the cell mediated immune response of renal failure patients. J Med 1992; 23: 289–302
   PubMedGoogle Scholar
• Shurtz-Swirski R, Kristal B, Shkolnik T, Weissman I, Shapiro G, Shasha SM. Short-term effect of erythropoietin on T-cell mitogenic proliferation in chronic renal failure patients. Nephron 1996; 72: 27–9
   PubMed Web of Science ®Google Scholar
• Sennesael JJ, Van der Niepen P, Verbeelen DL. Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 1991; 40: 121–8
   PubMed Web of Science ®Google Scholar
• Birmingham DJ, Shen XP, Hartman JA, Dillon JJ, Hebert LA. Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients. Kidney Int 1996; 50: 543–9
   PubMed Web of Science ®Google Scholar
• Schaefer RM, Paczek L, Berthold G, Gilge U, Heidland A. Improved immunoglobulin production in dialysis patients treated with recombinant erythropoietin. Int J Artif Organs 1992; 15: 204–8
   PubMed Web of Science ®Google Scholar
• Collart FE, Dratwa M, Wittek M, Wens R. Effects of recombinant human erythropoietin on T lymphocyte subsets in hemodialysis patients. ASAIO Trans 1990; 36: M219–23
   PubMedGoogle Scholar
• Ueki Y, Nagata M, Miyake S, Tominaga Y. Lymphocyte subsets in hemodialysis patients treated with recombinant human erythropoietin. J Clin Immunol 1993; 13: 279–87
   PubMed Web of Science ®Google Scholar
• Huraib S, Abu-Aisha H, al-Momen A, al-Wakeel J, Memon N, al-Tuwaijri A. Effect of recombinant human erythropoietin on lymphocyte phenotyping and phagocyte activity in hemodialysis patients. Am J Kidney Dis 1997; 29: 866–70
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41
   PubMed Web of Science ®Google Scholar
• Böyum A. Separation of lymphocytes from blood and bone marrow. Scand J Clin Lab Invest 1968; 21(Suppl)97
   Google Scholar
• Tala-Heikkila M, Nurmela T, Misljenovic O, Bleiker MA, Tala E. Sensitivity to PPD tuberculin and M. scrofulaceum sensitin in schoolchildren BCG vaccinated at birth. Tuber Lung Dis 1992; 73: 87–93
   PubMedGoogle Scholar
• Knight SC. Lymphocyte proliferation assays. Lymphocytes—a practical approach, GGB Klaus. IRL Press, London 1987; 189–207
   Google Scholar
• Alexiewicz JM, Gaciong Z, Klinger M, Linker-Israeli M, Pitts TO, Massry SG. Evidence of impaired T cell function in hemodialysis patients: potential role for secondary hyperparathyroidism. Am J Nephrol 1990; 10: 495–501
   PubMed Web of Science ®Google Scholar
• Cohen G, Haag-Weber M, Horl WH. Immune dysfunction in uremia. Kidney Int Suppl 1997; 62: S79–82
   PubMed Web of Science ®Google Scholar
• Girndt M, Sester U, Sester M, Kaul H, Kohler H. Impaired cellular immune function in patients with end-stage renal failure [editorial]. Nephrol Dial Transplant 1999; 14: 2807–10
   PubMed Web of Science ®Google Scholar
• Sutherland R, Delia D, Schneider C, Newman R, Kemshead J, Greaves M. Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin. Proc Natl Acad Sci U S A 1981; 78: 4515–9
   PubMed Web of Science ®Google Scholar
• Krantz SB. Erythropoietin. Blood 1991; 77: 419–34
   PubMed Web of Science ®Google Scholar
• Kimata H, Yoshida A, Ishioka C, Masuda S, Sasaki R, Mikawa H. Human recombinant erythropoietin directly stimulates B cell immunoglobulin production and proliferation in serum-free medium. Clin Exp Immunol 1991; 85: 151–6
   PubMed Web of Science ®Google Scholar
• Paczek L, Schaefer RM, Heidland A. Improved function of B lymphocytes in dialysis patients treated by recombinant human erythropoietin. Contrib Nephrol 1990; 87: 36–41
   PubMedGoogle Scholar
• Bárány P. Treatment of anemia in hemodialysis patients with recombinant human erythropoietin: clinical studies of the effects on nutrition, energy metabolism, work physiology, immune function and quality of life. University Press, Stockholm 1993
   Google Scholar
• Cavill I. Intravenous iron as adjuvant therapy: a two-edged sword?. Nephrol Dial Transplant 2003; 18(Suppl 8)viii24–8
   PubMedGoogle Scholar
• Bowlus CL. The role of iron in T cell development and autoimmunity. Autoimmun Rev 2003; 2: 73–8
   PubMed Web of Science ®Google Scholar
• Oppenheimer SJ. Iron and its relation to immunity and infectious disease. J Nutr 2001;131(2S-2):616S–33S; discussion 633S–5S.
   PubMed Web of Science ®Google Scholar